All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Despite the findings of the RATIFY study and the FDA approval of midostaurin, the survival of Acute Myeloid Leukemia (AML) patients harboring Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) mutations remains inferior due to possible underlying resistance mechanisms to targeted inhibitors that may decrease the effectiveness of these new approaches.1,2
On 20th February 2018, in Blood, Paolo Gallipoli from University of Cambridge, Cambridge, UK, and colleagues published results from their study, which aimed to identify novel cellular adaptive resistance mechanisms to FLT3-ITD tyrosine kinase (TK) inhibitor (TKI) treatment in FLT3-ITD mutated AML.
To do this, the authors performed an unbiased genome-wide CRISPR/Cas9 synthetic lethality screen on FLT3-ITD AML cell lines treated with a highly potent and specific FLT3-TKI (AC220 [quizartinib]). Gene analysis revealed that genes involved in metabolic pathways were highly regulated in FLT3-ITD AML cells after treatment with AC220. In particular, glutaminase (GLS), a mitochondrial enzyme that catalyses the conversion of glutamine to glutamate, was synthetically lethal with FLT3-TKI treatment. Gallipoli et al. further investigated the clinical role of GLS in FLT3-ITD AML cells treated with AC220.
In summary, these data confirm that glutamine metabolism is important in supporting the TCA cycle and redox metabolism in FLT3-ITD cells treated with AC220 in vitro. Using primary samples obtained from patients with FLT3-ITD AML, the authors found that AC220 treatment led to a reduction in glycolytic capacity. Additionally, combined treatment with AC220 and CB839 led to decreased basal oxygen consumption in primary AML samples. These data confirm that “combined targeting of FLT3 TK activity and glutamine metabolism decreases FLT3-ITD mutant cells leukemogenic potential in vitro and in vivo.”
The authors concluded by stating that their data highlights the “the role of metabolic adaptations as a resistance mechanism to several TKI, and suggests glutaminolysis as a therapeutically targetable vulnerability when combined with specific TKI in FLT3-ITD and other TK activating mutation driven leukemias.”
References